( September 29, 2026, 21:14 GMT | Official Statement) -- MLex Summary: Celgene, Teva, AbbVie and other companies failed to dismiss US claims that they conspired to illegally monopolize the market for Revlimid. District Judge Michae l E. Farbiarz denied the motion, finding a plausible showing of an anticompetitive pay-for-delay agreement between Celgene and smaller competitor Natco to keep a generic version of Revlimid. “The settlement agreement split up the market between a large player able to charge monopoly-type prices (Celgene) and a much smaller player (Natco) — and that structure would plausibly have allowed Natco to draft just behind the leader (Celgene), and to charge especially high per-unit prices for its generic Revlimid, much more than a generic usually goes for,” Farbiarz said. See attached file. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.